On September 21, 2018, the CBSA initiated an investigation respecting the alleged injurious dumping of nitisinone capsules from Sweden. The investigation follows a complaint filed by Laboratoirs KABS Inc. and MendeliKABS Inc.
The goods in question are normally classified under the following tariff classification numbers:
The subject goods are defined in the Complaint as:
Capsules and tablets of nitisinone with a dosage of 2 mg, 5 mg, 10 mg and 20 mg, whether or not they are packaged for retail, originating in or exported from the Kingdom of Sweden.
Additional product information can be found here.
The list of potential exporters and Statement of Reasons are here.
For the full list of documents filed with the CBSA so far, click here.
|September 21, 2018||Initiation of the CBSA’s dumping investigation|
|October 5, 2018||Statement of Reasons issued regarding the initiation of the investigations|
|October 15, 2018||Importer responses to CBSA’s Request for Information due|
|October 30, 2018||Exporter responses to CBSA’s Request for Information due|
|December 20, 2018||Preliminary Determinations or termination of the CBSA’s dumping investigation|
|January 4, 2019||Statement of Reasons issued (Preliminary Determinations or termination)|
In the event of preliminary determinations of dumping:
|December 20, 2018||Exporter and Importer ruling letters available|
|January 28, 2019, at noon||Closing of the Record date|
|February 4, 2019, by noon||Case Arguments due from all parties|
|February 11, 2019, by noon||Reply Submissions due from all parties in respect of Case Arguments|
|March 20, 2019||Final Determinations or termination of the CBSA’s dumping and subsidy investigations|
|March 20, 2019||Exporter and Importer ruling letters available|
|April 4, 2019||Statement of Reasons issued (Final Determinations or termination)|
The CITT has initiated at preliminary injury inquiry in order to determine whether the evidence discloses a reasonable indication that the dumping of capsules and tablets of nitisinone with a dosage of 2 mg, 5 mg, 10 mg and 20 mg, whether or not they are packaged for retail, originating in or exported from the Kingdom of Sweden, has caused injury or retardation or is threatening to cause injury, as these words are defined in SIMA.
We will be providing updates on this blog on the CBSA investigation and the CITT’s injury inquiry as they become available.
John Reiterowski, DS Lawyers Canada, LLP
DS Customs & Trade team located in Paris, Brussels, Montreal, Toronto, Lima, Singapore, Vietnam, Beijing, Guangzhou, Dakar and Cotonou is at your disposal to provide you with additional information.